BVS

Bioventus Inc.

Fundamental data last updated:August 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

 


VALUATION

P/E

20.96

Market Cap ($M USD)

$600.93M

Forward P/E

7.21

PEG

0.04

PRICE TO SALES

1.04

PRICE TO BOOK

3.16

EV / EBITDA

5.42

5-Year Average P/E

Free Cash Flow Yield

16.75%

DCF Value

$-2.35

Graham Number

$5.17

Price to FCF

5.97

EV to FCF

5.80

Earnings Yield

4.77%

FCF Yield

16.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.42

Next Year EPS Growth Estimate

$1.23

Next Year Revenue Growth Estimate

$793.38M

Return on Equity (ROE)

16.27%

FREE CASH FLOW

Operating Margin

10.64%

Debt-to-Equity

1.69

Piotroski F-Score

8

Altman Z-Score

1.55

Return on Invested Capital (ROIC)

12.21%

Current Ratio

1.69

Quick Ratio

1.13

Net Debt to EBITDA

-0.16

Interest Coverage

2.63

Gross Profit margin

67.78%

FCF PER SHARE

$1.50

REVENUE PER SHARE

$8.56

Gainseekers Quantitative Analysis

Summary

BVS Bioventus Inc. presents a perplexing valuation scenario. Despite a Forward P/E of 8.54 suggesting potential undervaluation, the stock’s price is alarmingly below its DCF Value, indicating possible market skepticism about future cash flows. The Graham Number further underscores this mispricing, hinting at a disconnect between intrinsic value and market perception. However, the Altman Z-score of 1.70 raises red flags about financial distress, while an Earnings Yield of 4.03% suggests limited immediate income potential. The market seems to be pricing in significant risk, possibly overlooking the company’s growth prospects.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, BVS is strategically positioned to leverage AI advancements in healthcare. The sector's shift towards tech-driven solutions could enhance product innovation and operational efficiency. However, the company's ability to integrate these technologies effectively remains to be seen.

The Bull Case

For the discerning value or GARP investor, BVS offers compelling reasons to buy. A robust ROIC of 12.16% indicates efficient capital deployment, while a Piotroski F-Score of 8 suggests strong financial health. The FCF Yield of 14.17% highlights substantial cash generation, and an Operating Margin of 10.60% reflects solid pricing power. These metrics paint a picture of a company capable of delivering sustainable returns, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, BVS faces significant structural risks. The Price/Book ratio of 3.74 and Price/Sales of 1.23 suggest the stock might be overvalued relative to its assets and revenue. Additionally, the stock's proximity to its 52-week high, with only a 7.13% distance, indicates potential technical overextension. While the debt levels are manageable, the market's current pricing could be overly optimistic, ignoring potential headwinds.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$13.00

Institutional Ownership %

1-Year Beta

0.72

Insider Buying % (6 Mo)

Distance to 52-Week High

26.82%

Distance to 52-Week Low

34.50%

EARNINGS SURPRISE %

66.67%

50-DAY SMA

$9.72

200-DAY SMA

$8.09

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.